Literature DB >> 2751973

Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes.

J Villumsen1, A Alm.   

Abstract

The effects of PGF2 alpha-isopropylester eye drops on intraocular pressure (IOP) and aqueous humour dynamics were investigated in healthy male volunteers. The other eye was treated with vehicle and used as a control. Special attention was also paid to adverse effects. Single and repeated doses were tested. There was a dose related effect on IOP. Significant reductions were observed 4, 8, and 12 hours after application of 1.0, 2.5, or 10 micrograms PGF2 alpha equivalents of the drug. With 10 micrograms the effect lasted 24 hours. An initial tendency towards an increase in IOP was observed for these doses. Repeated doses of 1.0 microgram daily or 0.5 microgram twice daily produced a significant and lasting IOP reduction of about 2 mmHg for 1-2 weeks. Aqueous humour production was not altered, and outflow facility was not significantly changed. There was a dose dependent hyperaemia with a maximum within 2 hours after application. A foreign body sensation, some pain, and photophobia were noted with increasing doses. A slight miosis of 1 mm was seen in three of six eyes treated with 10 micrograms. No signs of intraocular inflammation were recorded, but a slight increase in penetration of fluorescein into the anterior chamber was observed after 16 days of treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2751973      PMCID: PMC1041761          DOI: 10.1136/bjo.73.6.419

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits.

Authors:  C B Camras; L Z Bito; K E Eakins
Journal:  Invest Ophthalmol Vis Sci       Date:  1977-12       Impact factor: 4.799

2.  Uveoscleral drainage of aqueous humour in human eyes.

Authors:  A Bill; C I Phillips
Journal:  Exp Eye Res       Date:  1971-11       Impact factor: 3.467

3.  Effects of prostaglandin on blood flow in the rabbit eye.

Authors:  M S Starr
Journal:  Exp Eye Res       Date:  1971-03       Impact factor: 3.467

4.  Role of prostaglandin-mediated vasodilatation in inflammation.

Authors:  T J Williams; M J Peck
Journal:  Nature       Date:  1977-12-08       Impact factor: 49.962

5.  Prostaglandins: their disappearance from and release into the circulation.

Authors:  S H Ferreira; J R Vane
Journal:  Nature       Date:  1967-12-02       Impact factor: 49.962

6.  Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes.

Authors:  F A Stern; L Z Bito
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-05       Impact factor: 4.799

7.  Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha.

Authors:  K Crawford; P L Kaufman
Journal:  Arch Ophthalmol       Date:  1987-08

8.  Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys.

Authors:  K Crawford; P L Kaufman; B T Gabelt
Journal:  Curr Eye Res       Date:  1987-08       Impact factor: 2.424

9.  The effects of prostaglandins on the intraocular pressure of the rabbit.

Authors:  B R Beitch; K E Eakins
Journal:  Br J Pharmacol       Date:  1969-09       Impact factor: 8.739

10.  Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2 alpha.

Authors:  C B Camras; L Z Bito
Journal:  Curr Eye Res       Date:  1981       Impact factor: 2.424

View more
  23 in total

1.  Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.

Authors:  M Kimal Arici; A Topalkara; C Güler
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

2.  Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension.

Authors:  C Lindén; E Nuija; A Alm
Journal:  Br J Ophthalmol       Date:  1997-05       Impact factor: 4.638

3.  Correlation between individual differences in intraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma patients.

Authors:  Nobuhiko Kondo; Akira Sawada; Tetsuya Yamamoto; Toru Taniguchi
Journal:  Jpn J Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 2.447

4.  Can NSAIDs and prostaglandin analogues be combined?

Authors:  A Alm
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

5.  The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

Authors:  M Diestelhorst; S Roters; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

6.  Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

Authors:  J Villumsen; A Alm; M Söderström
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

Review 7.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  S S Patel; C M Spencer
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

8.  Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments.

Authors:  Cindy K Bahler; Kyle G Howell; Cheryl R Hann; Michael P Fautsch; Douglas H Johnson
Journal:  Am J Ophthalmol       Date:  2007-11-07       Impact factor: 5.258

Review 9.  Pharmacological advances in the treatment of glaucoma.

Authors:  J B Serle
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

10.  The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study.

Authors:  Sven Dinslage; Arno Hueber; Michael Diestelhorst; Günther Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.